Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Sect. Andinium W.Becker (113) S America Sect. Chamaemelanium Ging. s.lat. (61) N America, northeast Asia (includes Dischidium, Orbiculares) Subsect. Chamaemelanium Subsect. Nudicaules Subsect. Nuttalianae Sect. Chilenium W.Becker (8) southern S America Sect. Danxiaviola W. B. Liao et Q. Fan (1) China Sect. Delphiniopsis W.Becker (3) western Eurasia: southern Spain; Balkans Sect. Erpetion (Banks) W.Becker (11–18) eastern Australia; Tasmania Sect. Leptidium Ging. (19) S America Sect. Melanium Ging. (125) western Eurasia (pansies) Sect. Nosphinium W.Becker s.lat. (31–50) N, C and northern S America; Beringia; Hawaii Sect. nov. A (V. abyssinica group) (1–3) Africa: equatorial high mountains Sect. nov. B (V. spathulata group) (7–9) western and central Asia: northern Iraq to Mongolia Sect. Plagiostigma Godr. (120) northern hemisphere (includes Diffusae) Grex Primulifolia Sect. Rubellium W.Becker (3–6) S America: Chile Sect. Sclerosium W.Becker (1–4) northeastern Africa to southwestern Asia Sect. Tridens W.Becker (2) southern S America Sect. Viola s.str. (Rostellatae nom. illeg.) (75) northern hemisphere (violets) (includes Repentes) Subsect. Rostratae Kupffer (W.Becker) Subsect. Viola Sect. Xylinosium W.Becker (3–4) Mediterranean region
Lisa Sanders then questions if the episodes could be caused by an increase in stress, rooted by a traumatic stress episode within his early childhood involving custody actions between his mother and father. To help Matt out with the stress and psychological aspect of his illness, he was referred to a psychiatrist at Johns Hopkins that started him on cognitive behavioral therapy. While the cognitive therapy would help Matt out with his internal stress it might also help alleviate the severity of his episode until he is able to secure a valid diagnosis.
The new 38th district, much like its original iteration first used in the 2022 election (and historically the base of the original Houston-based iteration of the 7th district from 1966 until the 2022 redistricting), is based in west Houston and northwest Harris County, including all or parts of the west Houston neighborhoods of River Oaks, Tanglewood, Memorial City, Spring Branch and the Energy Corridor, as well as the communities of Jersey Village, Copperfield, Cypress, Champion Forest, Klein and Tomball in northwest Harris County. The incumbent is Republican Wesley Hunt, who was re-elected with 62.9% of the vote in 2024 and ran for the Republican nomination for U.S. Senate in 2026. Donald Trump won the district in 2024 with 59.5% of the vote, as did Ted Cruz (who resides in the district) with 56.6% of the vote.
The endocrine system consists of the principal endocrine glands: the pituitary, thyroid, adrenals, pancreas, parathyroids, and gonads, but nearly all organs and tissues produce specific endocrine hormones as well. The endocrine hormones serve as signals from one body system to another regarding an enormous array of conditions, resulting in variety of changes of function.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes (orthologs) are found across many species. As with many proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. The PCSK9 gene also contains one of 27 loci associated with increased risk of coronary artery disease. PCSK9 is ubiquitously expressed in many tissues and cell types. PCSK9 binds to and degrades the receptor for low-density lipoprotein particles (LDL), which typically transport 3,000 to 6,000 fat molecules (including cholesterol) per particle, within extracellular fluid. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells and targets the complex to lysosomes for destruction. If PCSK9 is blocked, the LDL-LDLR complex separates during trafficking, with the LDL digested in the lysosome, but the LDLRs instead recycled back to the cell surface and so able to remove additional LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations. PCSK9 has medical importance because it acts in lipoprotein homeostasis. Agents that block PCSK9 can lower LDL particle concentrations.
Sources: en.wikipedia.org
=== Science and technology === Turin had an astronomical observatory used by Giovanni Plana. The scientist Amedeo Avogadro worked as a professor in Turin. Galileo Ferraris, a professor at Turin University, discovered the working principles of the electric motor during the 19th century. In modern times, Turin hosted the CSELT telco laboratory.
=== 28 December === The Department of Foreign Affairs and Trade confirmed the death of Sage O’Donnell, the fourth Australian to die fighting for Ukraine. The Russian health ministry announced that it will permit Russian soldiers who had been fighting in Ukraine to have their sperm frozen in cryobanks for free. The Chief of the Main Intelligence Directorate of Ukraine, Kyrylo Budanov said that neither Ukraine nor Russian forces were able to advance.
=== Development from research tools === The industrialisation of molecular biology assay tools has made it practical to use them in clinics. Miniaturisation into a single handheld device can bring medical diagnostics into the clinic and into the office or home. The clinical laboratory requires high standards of reliability; diagnostics may require accreditation or fall under medical device regulations. As of 2011, some US clinical laboratories nevertheless used assays sold for "research use only". Laboratory processes need to adhere to regulations, such as the Clinical Laboratory Improvement Amendments, Health Insurance Portability and Accountability Act, Good Laboratory Practice, and Food and Drug Administration specifications in the United States. Laboratory Information Management Systems help by tracking these processes. Regulation applies to both staff and supplies. As of 2012, twelve US states require molecular pathologists to be licensed; several boards such as the American Board of Medical Genetics and the American Board of Pathology certify technologists, supervisors, and laboratory directors. Automation and sample barcoding maximise throughput and reduce the possibility of error or contamination during manual handling and results reporting. Single devices to do the assay from beginning to end are now available.
Salvia divinorum has large green ovate (often also dentate) leaves, with a yellow undertone that reach 10 to 30 cm (4 to 12 in) long. The leaves have no hairs on either surface, and little or no petiole. The plant grows to well over 1 metre (3 ft) in height, on hollow square stems which tend to break or trail on the ground, with the plant rooting quite readily at the nodes and internodes. The flowers, which bloom only rarely, grow in whorls on a 30-centimetre (12 in) inflorescence, with about six flowers to each whorl. The 3-centimetre (1+1⁄4 in) flowers are white, curved and covered with hairs, and held in a small violet calyx that is covered in hairs and glands. When it does bloom in its native habitat, it does so from September to May. Early authors erred in describing the flowers as having blue corollas, based on Epling and Játiva's description. The first plant material they received was dried, so they based the flower color on an erroneous description by Hofmann and Wasson, who didn't realize that their "blue flowers, crowned with a white dome" were in fact violet calyces with unopened white corollas.
==== Heart ==== Since the number of patients awaiting a heart transplant is continuously increasing over time, and the number of patients on the waiting list surpasses the organ availability, artificial organs used as replacement therapy for terminal heart failure would help alleviate this difficulty. Artificial hearts are usually used to bridge the heart transplantation or can be applied as replacement therapy for terminal heart malfunction. The total artificial heart (TAH), first introduced by Dr. Vladimir P. Demikhov in 1937, emerged as an ideal alternative. Since then it has been developed and improved as a mechanical pump that provides long-term circulatory support and replaces diseased or damaged heart ventricles that cannot properly pump the blood, restoring thus the pulmonary and systemic flow. Some of the current TAHs include AbioCor, an FDA-approved device that comprises two artificial ventricles and their valves, and does not require subcutaneous connections, and is indicated for patients with biventricular heart failure. In 2010 SynCardia released the portable freedom driver that allows patients to have a portable device without being confined to the hospital.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.